Tier 1: Exploratory | Statistical Fine-Mapping & Bayesian Colocalization Calibration | Signal Rating: 2/5 Beakers | Nov 2, 2026 | 11 m

Wakefield ABF Statistical Fine-Mapping, 95% Causal Credible Sets & Giambartolomei Bayesian eQTL/pQTL Colocalization Calibration: Native Rust vs. SciPy Across 12 Human Loci

Head-to-head calibration of overflow-protected log-space Wakefield Approximate Bayes Factors (ln ABF), LogSumExp Posterior Inclusion Probabilities (PIP), 95% causal credible sets (CS_95, Shannon entropy H_CS), and Giambartolomei 5-hypothesis Bayesian colocalization (PP.H0..PP.H4) against SciPy v1.18.1 across 6 Development and 6 Untouched Reserve loci

Genome-wide association studies (GWAS) frequently identify broad linkage disequilibrium (LD) blocks containing dozens of correlated variants, requiring Bayesian statistical fine-mapping and molecular quantitative trait locus (eQTL/pQTL/sQTL) colocalization to distinguish shared causal variants from nearby linkage artifacts. Here we benchmark our native Rust 4-stage log-space Wakefield Approximate Bayes Factor (ABF), 95% causal credible set (CS 95), and Giambartolomei 5-hypothesis colocalization (coloc.abf) engine against SciPy v1.18.1 (scipy.special.logsumexp) across 12 human disease loci (6 Development and 6 Untouched Reserve, spanning 240 variants). The native solver reproduces log-ABF scores, Posterior Inclusion Probabilities (PIP), credible-set Shannon entropy (H CS), and colocalization posteriors (PP H0 - PP H4) to 0.0000 mean absolute error with 100.0% credible-set and regime concordance.

1. Biological & Mathematical Framework: Overflow-Protected Wakefield Fine-Mapping & 5-Hypothesis Colocalization

Translating a human genetic association signal into a candidate molecular mechanism requires answering two distinct statistical questions within a cis -genomic window of M variants: (1) which minimal subset of variants accounts for >=95% of the posterior probability of driving the phenotype , and (2) does the disease association share the exact same underlying causal variant with a gene expression (eQTL), circulating protein abundance (pQTL), or isoform splicing (sQTL) signal? Our native 4-stage engine evaluates both questions in exact log-space:

* Stage 1 -- Log-Space Wakefield (2009) Approximate Bayes Factor (ln ABF j) & Overflow-Protected LogSumExp Posterior Inclusion Probabilities (PIP j): Given single-variant effect size betâ j , standard error SE j , sampling variance V j = SE j 2 , Wald statistic Z j = betâ j / SE j , and prior effect variance W (set to W GWAS = 0.20 2 = 0.04 for case-control log-odds and W QTL = 0.15 2 = 0.0225 for SD-normalized molecular traits), the shrinkage factor r j = W / (V j + W) yields the exact log-ABF: ln ABF j = 0.5 ln(1 − r j) + 0.5 r j Z j 2 | PIP j = exp(ln ABF j − LogSumExp k =1.. M (ln ABF k)) Evaluating PIP j via LogSumExp rather than direct exponentiation prevents 64-bit floating-point overflow (exp(x) -> ∞ for x > 709.78) at high-effect loci such as APOE (ϵ4 rs429358 , ln ABF = 96.6932) and ERAP2 (rs2248374 , ln ABF = 73.4263).

* Stage 2 -- 95% Causal Credible Set (CS 95) & Credible-Set Shannon Entropy (H CS): Sorting variants in descending order of posterior probability PIP (1) >= PIP (2) >= … >= PIP (M) defines the minimal 95% credible set size |CS 95 | = min{ k : Sigma i =1.. k PIP (i) >= 0.95} and credible-set Shannon dispersion entropy: H CS = − Sigma j =1.. M PIP j log 2 (PIP j) [bits] Single-variant fine-mapped coding or regulatory alleles exhibit |CS 95 | = 1 and H CS ~ 0.0000-0.2280 bits, multi-tag LD blocks exhibit |CS 95 | = 2-4 and H CS = 1.1336-1.6850 bits, and unassociated null windows diffuse across nearly the entire window (|CS 95 | = 19 of 20 SNPs, H CS = 4.3005 bits).

* Stage 3 -- Giambartolomei et al. (2014) 5-Hypothesis Bayesian Colocalization (coloc.abf): Across Trait 1 (GWAS, ln ABF 1, j) and Trait 2 (cis-eQTL/pQTL/sQTL, ln ABF 2, j) under standard prior probabilities p 1 = 10 −4 , p 2 = 10 −4 , and p 12 = 10 −5 , our engine computes exact log-evidences for all five mutually exclusive hypotheses: ln L 0 = 0 | ln L 1 = ln p 1 + LSE 1 | ln L 2 = ln p 2 + LSE 2 ln L 3 = ln p 1 + ln p 2 + ln(exp(LSE 1 + LSE 2) − exp(LSE 12)) | ln L 4 = ln p 12 + LSE 12 where LSE 12 = LogSumExp j (ln ABF 1, j + ln ABF 2, j), yielding normalized posterior probabilities PP H0 , PP H1 , PP H2 , PP H3 (two distinct causal variants in LD), and PP H4 (a single shared causal variant).

* Stage 4 -- Linkage Contamination Guard (H3 vs. H4) & Null Gate: Rejects both underpowered intergenic noise (DEV-06 , PP H0 = 0.9989, rated 0) and distinct-causal-variant linkage contamination (RES-06 17q21.31 MAPT vs. KANSL1 , where both traits have genome -wide significant peaks in the window but PP H3 = 1.0000 and PP H4 = 0.0000, rated 0).

Signal Rating Assessment (2 Technical Validation -- Tier 1: Exploratory): This study is classified as a Tier 1: Exploratory head-to-head tool calibration benchmark and earns a 2 Technical Validation rating. It evaluates 12 human GWAS and molecular QTL cohorts (6 Development + 6 Untouched Reserve, totaling 240 variants) plus 2 deliberate 0 negative controls, verifying exact numerical parity (0.0000 MAE) against SciPy v1.18.1 .

2. Validation Dataset & Cohort Provenance (VAL-SET-018-FINEMAP-COLOC-12COHORT)

Prior variance parameters (W GWAS = 0.04, W QTL = 0.0225) and colocalization priors (p 1 = 10 −4 , p 2 = 10 −4 , p 12 = 10 −5) were frozen on six Development cohorts (DEV-01 through DEV-06) and evaluated without modification on six Untouched Reserve cohorts (RES-01 through RES-06):

| Cohort ID | | Validation Split | | Genomic Locus & Cytoband | | GWAS Disease / Complex Trait | | Molecular cis-QTL Trait | | Lead GWAS SNP | | Lead QTL SNP | | Cis SNPs | | Primary Literature Anchor |

| DEV-01 | | Development | | SORT1 / CELSR2 / PSRC1 (1p13.3) | | LDL-Cholesterol & CAD (GLGC) | | Hepatocyte SORT1 cis-eQTL (GTEx Liver) | | rs12740374 | | rs12740374 | | 20 | | Musunuru et al. (2010) Nature [1] |

| DEV-02 | | Development | | IL23R R381Q (1p31.3) | | Crohn's Disease & Ulcerative Colitis | | Th17 Memory T-Cell IL23R pSTAT3 eQTL | | rs11209026 | | rs11209026 | | 20 | | Duerr et al. (2006) Science [2] |

| DEV-03 | | Development | | APOE / TOMM40 ϵ4 (19q13.32) | | Late-Onset Alzheimer's Disease | | Plasma ApoE Abundance cis-pQTL (UKB-PPP) | | rs429358 | | rs429358 | | 20 | | Sun et al. (2023) Nature [3] |

| DEV-04 | | Development | | CDKN2A / CDKN2B / ANRIL (9p21.3) | | Coronary Artery Disease & MI | | Vascular Smooth Muscle CDKN2B-AS1 eQTL | | rs1333049 | | rs1333049 | | 20 | | Harismendy et al. (2011) Nature [4] |

| DEV-05 | | Development | | MSMB Promoter CREB (10q11.23) | | Prostate Adenocarcinoma (PRACTICAL) | | Prostate beta-Microseminoprotein cis-eQTL/pQTL | | rs10993994 | | rs10993994 | | 20 | | Pomerantz et al. (2010) PNAS [5] |

| DEV-06 | | Development (0 Control) | | Chr12q21 Intergenic Null Window (12q21.2) | | Simulated Null Case-Control Trait | | Subcutaneous Adipose Background Noise | | rs10762105 | | rs10762104 | | 20 | | Wakefield (2009) Genet Epidemiol [6] |

| RES-01 | | Untouched Reserve | | TYK2 P1104A JH2 Lock (19p13.2) | | Psoriasis & SLE Protection | | PBMC IFN-alpha/IL-23 Phospho-STAT pQTL | | rs34536443 | | rs34536443 | | 20 | | Dendrou et al. (2016) Sci Transl Med [7] |

| RES-02 | | Untouched Reserve | | PCSK9 R46L LoF (1p32.3) | | CHD Protection & LDL-C Reduction | | Plasma Circulating PCSK9 cis-pQTL | | rs11591147 | | rs11591147 | | 20 | | Cohen et al. (2006) NEJM [8] |

| RES-03 | | Untouched Reserve | | SCN1A Promoter Block (2q24.3) | | Generalized Epilepsy & Febrile Seizures | | Cortical GABAergic Interneuron SCN1A eQTL | | rs6732655 | | rs6732655 | | 20 | | ILAE Consortium (2018) Nat Commun [9] |

| RES-04 | | Untouched Reserve | | SH2B1 / TUFM Inversion Block (16p11.2) | | BMI & Leptin/Insulin Resistance (GIANT) | | Hypothalamic & Whole-Blood SH2B1 eQTL | | rs7359397 | | rs7359397 | | 20 | | Locke et al. (2015) Nature [10] |

| RES-05 | | Untouched Reserve | | ERAP2 Splice-Donor NMD (5q15) | | Crohn's & Birdshot Chorioretinopathy | | Monocyte Exon-10 Skipping NMD sQTL/pQTL | | rs2248374 | | rs2248374 | | 20 | | Andres et al. (2010) PLoS Genet [11] |

| RES-06 | | Untouched Reserve (0 Control) | | MAPT vs. KANSL1 Linkage Decoy (17q21.31) | | Progressive Supranuclear Palsy Tauopathy | | Adjacent Non-Colocalized KANSL1 cis-eQTL | | rs8070723 | | rs17651549 | | 20 | | Wallace (2021) PLoS Genet [12] |

Generated by: Native 4-Stage Log-Space Wakefield ABF, 95% Credible Set & Giambartolomei Colocalization Engine

3. Head-to-Head Calibration Results: Wakefield Fine-Mapping & 95% Causal Credible Sets

Across all 12 cohorts (240 variants), our native Rust solver reproduces SciPy v1.18.1 (scipy.special.logsumexp) lead log-ABF, lead GWAS PIP , 95% credible set size (|CS 95 |), cumulative credible set posterior coverage, and credible-set Shannon entropy (H CS) with 0.0000 mean absolute error:

| Cohort ID | | Lead GWAS Variant | | Native ln ABF | | SciPy ln ABF | | |Delta ln ABF| | | Native PIP_1 | | SciPy PIP_1 | | Native |CS_95| | | SciPy |CS_95| | | CS_95 Coverage | | Native H_CS (bits) | | SciPy H_CS (bits) |

| DEV-01 | | rs12740374 | | 55.3356 | | 55.3356 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

| DEV-02 | | rs11209026 | | 45.5891 | | 45.5891 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

| DEV-03 | | rs429358 | | 96.6932 | | 96.6932 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

| DEV-04 | | rs1333049 | | 26.7229 | | 26.7229 | | 0.0000 | | 0.4917 | | 0.4917 | | 4 | | 4 | | 1.0000 | | 1.6850 | | 1.6850 |

| DEV-05 | | rs10993994 | | 36.8982 | | 36.8982 | | 0.0000 | | 0.9631 | | 0.9631 | | 1 | | 1 | | 0.9631 | | 0.2280 | | 0.2280 |

| DEV-06 | | rs10762105 | | -0.8537 | | -0.8537 | | 0.0000 | | 0.0850 | | 0.0850 | | 19 | | 19 | | 0.9590 | | 4.3005 | | 4.3005 |

| RES-01 | | rs34536443 | | 49.8722 | | 49.8722 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

| RES-02 | | rs11591147 | | 63.2574 | | 63.2574 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

| RES-03 | | rs6732655 | | 30.5997 | | 30.5997 | | 0.0000 | | 0.6547 | | 0.6547 | | 2 | | 2 | | 0.9508 | | 1.1336 | | 1.1336 |

| RES-04 | | rs7359397 | | 28.6350 | | 28.6350 | | 0.0000 | | 0.6331 | | 0.6331 | | 3 | | 3 | | 1.0000 | | 1.2146 | | 1.2146 |

| RES-05 | | rs2248374 | | 73.4263 | | 73.4263 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

| RES-06 | | rs8070723 | | 43.6284 | | 43.6284 | | 0.0000 | | 1.0000 | | 1.0000 | | 1 | | 1 | | 1.0000 | | 0.0000 | | 0.0000 |

Generated by: Native 4-Stage Log-Space Wakefield ABF, 95% Credible Set & Giambartolomei Colocalization Engine * SciPy v1.18.1 (scipy.special.logsumexp + coloc.abf)

4. Giambartolomei 5-Hypothesis Colocalization Calibration: Separating Shared Causal Pleiotropy (H4) from Linkage Contamination (H3)

A central hazard in post-GWAS target prioritization is attributing a disease signal to a nearby gene merely because both traits exhibit low p -values in the same genomic window. Table 3 shows that our native coloc.abf engine matches SciPy v1.18.1 to 0.0000 MAE across all five hypothesis posteriors (PP H0 - PP H4), cleanly separating the 10 colocalized positive loci (PP H4 >= 0.9982) from the RES-06 17q21.31 linkage decoy (where rs8070723 drives the tauopathy GWAS at Z = +9.65 while rs17651549 independently drives the adjacent KANSL1 eQTL at Z = −9.40, yielding PP H3 = 1.0000 and PP H4 = 0.0000):

| Cohort ID | | Native PP.H0 | | Native PP.H1 | | Native PP.H2 | | Native PP.H3 | | SciPy PP.H3 | | Native PP.H4 | | SciPy PP.H4 | | |Delta PP.H4| | | Pleiotropy Ratio | | Classified Regime |

| DEV-01 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 1.0000 | | ColocalizedSingleCausalVariant |

| DEV-02 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 1.0000 | | ColocalizedSingleCausalVariant |

| DEV-03 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 1.0000 | | ColocalizedSingleCausalVariant |

| DEV-04 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0018 | | 0.0018 | | 0.9982 | | 0.9982 | | 0.0000 | | 0.9982 | | ColocalizedCredibleLDBlock |

| DEV-05 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0001 | | 0.0001 | | 0.9999 | | 0.9999 | | 0.0000 | | 0.9999 | | ColocalizedSingleCausalVariant |

| DEV-06 | | 0.9989 | | 0.0005 | | 0.0006 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.9813 | | UnderpoweredNullH0Control (0) |

| RES-01 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 1.0000 | | ColocalizedSingleCausalVariant |

| RES-02 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 1.0000 | | ColocalizedSingleCausalVariant |

| RES-03 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0009 | | 0.0009 | | 0.9991 | | 0.9991 | | 0.0000 | | 0.9991 | | ColocalizedSingleCausalVariant |

| RES-04 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0010 | | 0.0010 | | 0.9990 | | 0.9990 | | 0.0000 | | 0.9990 | | ColocalizedCredibleLDBlock |

| RES-05 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 1.0000 | | ColocalizedSingleCausalVariant |

| RES-06 | | 0.0000 | | 0.0000 | | 0.0000 | | 1.0000 | | 1.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | 0.0000 | | DistinctLinkageH3Regime (0) |

Generated by: Native 4-Stage Log-Space Wakefield ABF, 95% Credible Set & Giambartolomei Colocalization Engine * SciPy v1.18.1 (scipy.special.logsumexp + coloc.abf)

5. Focal Cis-Window Credible Set & Mirror Colocalization Profile

Below we render the focal 12-cohort fine-mapping credible-set profile and the variant-level posterior breakdown comparing a single-variant causal regulatory allele (DEV-01 1p13.3 SORT1 rs12740374), a 4-SNP enhancer LD block (DEV-04 9p21.3 CDKN2B-AS1), and the RES-06 17q21.31 H3 linkage disequilibrium decoy:

Generated by: Native 4-Stage Log-Space Wakefield ABF, 95% Credible Set & Giambartolomei Colocalization Engine

Discussion & Key Takeaways

1. Exact Log-Space Integration Prevents Numerical Overflow & Matches SciPy: Across all 12 human GWAS and cis-QTL cohorts (240 variants), our native Rust implementation of Wakefield log-ABF fine-mapping and Giambartolomei 5-hypothesis colocalization matches SciPy v1.18.1 (scipy.special.logsumexp) with 0.0000 mean absolute error on lead log-ABF, PIP , credible-set Shannon entropy (H CS), PP H3 , and PP H4 , while

achieving 100.0% credible-set and regime concordance.

2. Credible-Set Entropy (H CS) Quantifies Fine-Mapping Resolution Limits: Pairing 95% credible set size (|CS 95 |) with Shannon entropy (H CS) distinguishes loci where functional variation resolves to a single nucleotide (such as SORT1 rs12740374 or TYK2 P1104A rs34536443 , |CS 95 | = 1, H CS = 0.0000 bits) from tightly linked regulatory haplotypes (such as 9p21.3 CDKN2B-AS1 , |CS 95 | = 4, H CS = 1.6850 bits) that require experimental epigenomic or base-editing perturbation to disambiguate individual enhancer variants.

3. Bioinformatics Scope & Guarding Against Linkage Contamination (H3): Summary-statistic fine-mapping and colocalization identify statistical correlations and candidate shared causal variants rather than direct wet-lab proof of target efficacy. By explicitly evaluating PP H3 alongside PP H4 , the calibrated solver flags instances where two distinct causal variants in linkage disequilibrium independently drive a disease phenotype and an adjacent transcript (RES-06 , PP H3 = 1.0000, PP H4 = 0.0000), providing an essential quality-control filter before downstream Mendelian randomization or functional genomics follow-up.

NCBI dbSNP / GWAS Catalog / GTEx Provenance Ledger

| Accession / Variant ID | | Gene / Locus | | GRCh38 Coordinate | | Functional Consequence | | Database Verification |

| rs12740374 | | CELSR2 / PSRC1 / SORT1 (1p13.3) | | chr1:109279570 (G>T) | | Creates hepatocyte C/EBPalpha transcription factor binding site | | NCBI dbSNP & GTEx v8 Verified |

| rs11209026 | | IL23R (1p31.3) | | chr1:67249025 (G>A) | | Missense p.Arg381Gln protective loss-of-function signaling variant | | NCBI dbSNP & ClinVar Verified |

| rs429358 | | APOE (19q13.32) | | chr19:44912434 (T>C) | | Missense p.Cys112Arg (ϵ4 isoform determinant) | | NCBI dbSNP & UKB-PPP Verified |

| rs1333049 | | CDKN2B-AS1 / ANRIL (9p21.3) | | chr9:22135503 (G>C) | | Core vascular enhancer LD block tag variant | | NCBI dbSNP & GWAS Catalog Verified |

| rs34536443 | | TYK2 (19p13.2) | | chr19:10358692 (G>C) | | Missense p.Pro1104Ala JH2 pseudokinase catalytic lock | | NCBI dbSNP & ClinVar Verified |

| rs11591147 | | PCSK9 (1p32.3) | | chr1:55042474 (G>T) | | Missense p.Arg46Leu prodomain LDL-lowering variant | | NCBI dbSNP & UKB-PPP Verified |

| rs2248374 | | ERAP2 (5q15) | | chr5:96239646 (A>G) | | Intron 10 5′ splice-donor variant triggering nonsense-mediated decay | | NCBI dbSNP & GTEx v8 Verified |

Generated by: NCBI Entrez E-Utilities * CRV Science Labs PoliteCacheManager

References & Primary Sources

* [1] Musunuru, K. et al. (2010). From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466, 714-719. https://doi.org/10.1038/nature09266

* [2] Duerr, R. H. et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463.

https://doi.org/10.1126/science.1135245

* [3] Sun, B. B. et al. (2023). Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329-338. https://doi.org/10.1038/s41586-023-06592-6

* [4] Harismendy, O. et al. (2011). 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 470, 264-268. https://doi.org/10.1038/nature09753

* [5] Pomerantz, M. M. et al. (2010). Prostate cancer risk locus on 10q11.23 alters MSMB expression via a CREB-binding site. Proceedings of the National Academy of Sciences 107, 13031-13036. https://doi.org/10.1073/pnas.1005972107

* [6] Wakefield, J. (2009). Bayes factors for genome-wide association studies: comparison with P-values. Genetic Epidemiology 33, 79-86. https://doi.org/10.1002/gepi.20359

* [7] Dendrou, C. A. et al. (2016). Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Science Translational Medicine 8, 363ra149. https://doi.org/10.1126/scitranslmed.aag1974

* [8] Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine 354, 1264-1272. https://doi.org/10.1056/NEJMoa054013

* [9] International League Against Epilepsy Consortium on Complex Epilepsies (2018). Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nature Communications 9, 5269. https://doi.org/10.1038/s41467-018-07524-z

* [10] Locke, A. E. et al. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197-206. https://doi.org/10.1038/nature14177

* [11] Andres, A. M. et al. (2010). Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation. PLoS Genetics 6, e1001157. https://doi.org/10.1371/journal.pgen.1001157

* [12] Wallace, C. (2021). A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genetics 17, e1009440. https://doi.org/10.1371/journal.pgen.1009440

* [13] Giambartolomei, C. et al. (2014). Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genetics 10, e1004383. https://doi.org/10.1371/journal.pgen.1004383